Danske Bank A S Grows Stock Position in Labcorp Holdings Inc. $LH

Key Points

• Danske Bank A/S raised its position in Labcorp by 17.1%, buying 6,080 shares to hold 41,602 shares worth about $10.44M (≈0.05% of the company) at the end of the quarter.
• Labcorp beat Q1 estimates with EPS $4.25 vs. $4.09 and revenue $3.54B vs. $3.51B, issued FY2026 guidance of 17.70–18.35 EPS, and carries a consensus analyst target of $308 (Moderate Buy).
• Institutional ownership is very high at 95.94%, with notable recent moves such as Goldman Sachs boosting its stake 52.2% to 353,843 shares and several funds adding new or larger positions.

Danske Bank A S raised its position in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 17.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,602 shares of the medical research company's stock after buying an additional 6,080 shares during the period. Danske Bank A S owned approximately 0.05% of Labcorp worth $10,437,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LH. Brighton Jones LLC purchased a new position in Labcorp in the 4th quarter valued at about $991,000. Integrated Wealth Concepts LLC boosted its stake in shares of Labcorp by 7.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company's stock valued at $565,000 after buying an additional 177 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Labcorp by 52.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company's stock valued at $82,353,000 after buying an additional 121,304 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Labcorp during the 2nd quarter valued at approximately $5,873,000. Finally, First Trust Advisors LP boosted its stake in shares of Labcorp by 83.2% during the 2nd quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company's stock valued at $22,588,000 after buying an additional 39,087 shares during the last quarter. 95.94% of the stock is owned by hedge funds and other institutional investors.

Labcorp Stock Performance

Shares of LH opened at $252.99 on Tuesday. The business's fifty day moving average price is $270.69 and its 200 day moving average price is $267.33. Labcorp Holdings Inc. has a 12-month low of $239.67 and a 12-month high of $293.72. The stock has a market capitalization of $20.79 billion, a PE ratio of 22.41, a price-to-earnings-growth ratio of 1.72 and a beta of 0.91. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.51 billion. During the same period last year, the business posted $3.84 earnings per share. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities research analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. Labcorp's dividend payout ratio (DPR) is currently 25.51%.

Analysts Set New Price Targets

Several research firms have recently commented on LH. JPMorgan Chase & Co. increased their target price on Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Piper Sandler increased their target price on Labcorp from $270.00 to $300.00 and gave the company a "neutral" rating in a research note on Tuesday, February 24th. Morgan Stanley reaffirmed an "overweight" rating on shares of Labcorp in a research report on Tuesday, February 17th. Robert W. Baird set a $334.00 price target on shares of Labcorp in a research report on Friday. Finally, Evercore reaffirmed an "outperform" rating and set a $300.00 price target on shares of Labcorp in a research report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Labcorp currently has a consensus rating of "Moderate Buy" and an average target price of $308.00.

Insider Buying and Selling at Labcorp

In other Labcorp news, EVP Jonathan C. Meltzer sold 87 shares of the firm's stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president owned 2,782 shares of the company's stock, valued at $807,948.44. This trade represents a 3.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Brian J. Caveney sold 1,500 shares of the firm's stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the completion of the transaction, the executive vice president directly owned 30,107 shares in the company, valued at $8,619,935.17. This represents a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 16,113 shares of company stock worth $4,547,450. Insiders own 0.84% of the company's stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.